LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships [Yahoo! Finance]
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: Yahoo! Finance
Presbyopia is a normal part of aging, making it difficult to see objects up close. In this China Phase 3 safety and efficacy trial, LNZ100 (1.75% aceclidine HCl) achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near and maintaining their optimal distance visual acuity (i.e., not losing five or more letters). More results showed (all p 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes, respectively. 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours, respectively, and maintained their optimal distance visual acuity. 61% and 30% achieved two-line and three-line or greater improvement at 10 hours, respectively. LNZ100 was well-tolerated, and no serious treatment-related adverse events were observed in the trial. With an Outperform rating , William Blair highlights the impressive consi
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- LENZ Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire
LENZ
Earnings
- 11/6/24 - Beat
LENZ
Sec Filings
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- 11/6/24 - Form 424B3
- LENZ's page on the SEC website